DuoADCTM Precision Engagement, Amplified Efficacy
Redefine ADC efficacy ceilings—DuoADCTM merges computationally guided target pairing with mechanistically validated co-internalization for maximized payload impact.
Learn More
Redefine ADC efficacy ceilings—DuoADCTM merges computationally guided target pairing with mechanistically validated co-internalization for maximized payload impact.
Learn More
Screens optimal antibody pairs and combination strategies by simultaneously evaluating dual-target binding activity, internalization efficiency, and dynamic intracellular co-localization.
Provides customized development of cleav-able/non-cleavable linkers, balancing circulatory stability with tumor microenvironment-specific payload release to enhance ADC therapeutic window.
Designs differentiated payload release mecha-nisms and kinetics to achieve spatiotemporal synergistic killing effects with dual payloads (e.g., tubulin inhibitor + DNA damaging agent).
Designs differentiated payload release mecha-nisms and kinetics to achieve spatiotemporal synergistic killing effects with dual payloads (e.g., tubulin inhibitor + DNA damaging agent).
Alfa Cytology, based in New York, USA, is a research solutions provider, focused on cancer therapeutic development and preclinical studies.
Scientific
Excellence
Customized
Solutions
Collaborative
Approach
Data
Security
Precisely quantifies ADC-specific cytotoxicity against target-positive cells and transmembrane bystander effects using high-content imaging and 3D tumor spheroid models.
Learn More
Comprehensively evaluates ADC efficacy through PDX/CDX models, measuring tumor growth inhibition, dose-response relationships, and therapeutic index.
Learn More
Monitors ADC plasma stability, tissue distribu-tion, and metabolic pathways by radioisotope tracing coupled with LC-MS/MS to track intact ADCs and free payloads.
Learn More
Defines ADC safety windows and off-target toxicity profiles through multi-organ toxicity profiling and immunogenicity assessment.
Learn More
Integrated Conjugation Workflow
Precision Characterization Platform
Interdisciplinary Technology Team
End-to-end Quality Assurance Platform
As a committed preclinical research service provider focused on cancer, Alfa Ctytology’s one-stop drug discovery services and a range of technology platforms will address the diverse needs of our clients, guaranteeing innovative and effective research results.
Learn MoreAlfa Cytology specializes in the development of innovative antibody-drug conjugates (ADCs) for breast cancer therapies, leveraging the specificity of monoclonal antibodies and the potency of cytotoxic drugs.
Learn MoreAt Alfa Cytology, we offer a comprehensive suite of preclinical services tailored to advance cancer research and drug development. Our one-stop preclinical platform provides end-to-end solutions, from disease modeling and diagnostic development to therapeutic evaluation - all under one roof.
Learn MoreSingle B cell technology has emerged as a powerful method for discovering and developing antibodies, particularly in the context of cancers like bladder cancer.
Learn MoreAlfa Cytology is committed to providing valuable insights on selecting appropriate in-vivo models for evaluating the effectiveness of cancer immunotherapy. Our skills assist in navigating the vast array of options, facilitating high-quality research in this crucial area of oncology.
Learn MoreAlfa Cytology was proud to participate in Cancer R&D 2024, where they presented a session titled "Designing Your Preclinical Cancer Modeling Mouse Studies," showcasing their expertise and innovative approaches in developing and optimizing mouse models for preclinical cancer research.
Learn MoreWhen choosing the right service provider for cancer therapy development, it’s essential to consider factors like experience, expertise, and support. Alfa Cytology is here to guide you through this critical selection process.
Learn MoreThe Cell Line Derived Xenograft (CDX) model plays a crucial role in oncology research. At Alfa Cytology, we have mastered the art and science of CDX model development, offering a comprehensive range of services tailored to meet the diverse needs of our clients.
Learn More
Alfa Cytology, a preclinical research solution provider, provides its clients with one-stop solutions to accelerate cancer therapeutics discovery and development.
Copyright © 2026 Alfa Cytology. All rights reserved.
